Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

Abstract: The present disclosure relates to composition comprising Trigofoenoside, Vitexin, Iso-vitexin, Vitexin-2-o-rhamnoside Vicenin-1 and fiber, optionally along with pharmaceutically acceptable excipient(s) and method(s) of preparing said composition. The present disclosure also relates to methods of treating various conditions such as, but not limited to, Hypoxia, ulmonary Hypertension, Pulmonary Fibrosis and Sinusitis using the said composition.

Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

Abstract: The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability.

Abstract: The present disclosure relates to management of Hepatitis C Virus (HCV) and associated condition. The present disclosure also relates to management of Hepatic Fibrosis. The present disclosure relates to administration of composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutically acceptable excipient, for management of Hepatic Fibrosis, Hepatitis C virus and associated conditions. The composition acts as an inhibitor at the entry stage of Hepatitis C virus into a cell. The composition inhibits different genotypes of Hepatitis C Virus.

Abstract: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.

Abstract: The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.

Abstract: The present invention relates to a novel pharmaceutical composition for serotonin reuptake inhibition, wherein the composition comprises pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients. Also the present invention relates to a process of preparation of novel pharmaceutical composition for serotonin reuptake inhibition, wherein the process comprising steps of: (a) obtaining extract from the plant Centella asiatica; (b) treating the extract with the solvents to remove fatty substances, chlorophyll and other colorants; (c) purifying the extract through HPLC to obtain the eluted solvent; and (d) concentrating the eluted solvent to arrive at the composition. The invention also relates to the use of a composition comprising pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients to manufacture a medicament for serotonin reuptake inhibition in a subject in need thereof.

Abstract: The present disclosure relates to management of Hepatitis C Virus (HCV) and associated condition. The present disclosure also relates to management of Hepatic Fibrosis. The present disclosure relates to administration of composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutically acceptable excipient, for management of Hepatic Fibrosis, Hepatitis C virus and associated conditions. The composition acts as an inhibitor at the entry stage of Hepatitis C virus into a cell. The composition inhibits different genotypes of Hepatitis C Virus.

Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

Abstract: The present disclosure relates to treatment and management of Cushing's syndrome, Headache disorders and Neuropathic using a composition comprising asiaticoside and madecasosside optionally along with at least one excipient. The treatment can be extended to Myalgia and other related disease conditions.

Abstract: The present disclosure relates to a method of managing urolithiasis or related urological disorders in a subject in need thereof, using pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipient(s).

Abstract: Disclosed is a commercially viable asiaticoside composition having at least 99% purity that is derived from plant Centella asiatica and a manufacturing process thereof. Also disclosed is a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Inflammatory Bowel Diseases such as Ulcerative colitis, Crohn's disease and associated complications of inflammatory bowel diseases such as hemorrhoids, anal fissures, fistulas. Also disclosed is a method and model for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Helicobacter Pylori, as well as a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for prevention of colon cancer, gastric diseases and gastric carcinoma.

Abstract: The present disclosure is in relation to antiviral preparations obtained from plant sources namely Cinnamon, Litchi and Arachis. It provides a composition and a process to prepare the composition comprising pentameric procyanidin flavonoid, trimers and tetramers. The composition improves immunity response and found to be useful in treatment and management of HIV infection and AIDS and for the prevention, treatment and management of Influenza virus and infection.

Abstract: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.

Abstract: The present disclosure is in relation to the use of a composition comprising pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally along with pharmaceutical excipient(s), in management of broncho-constrictive conditions such as Allergic Rhinitis, Asthma, and Chronic obstructive pulmonary disease (COPD).

Abstract: The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from Trigonella foenum-graecum.

Abstract: Disclosed is a commercially viable asiaticoside composition having at least 99% purity that is derived from plant Centella asiatica and a manufacturing process thereof. Also disclosed is a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Inflammatory Bowel Diseases such as Ulcerative colitis, Crohn's disease and associated complications of inflammatory bowel diseases such as hemorrhoids, anal fissures, fistulas. Also disclosed is a method and model for oral administration of therapeutically effective amounts of the asiaticoside composition for treatment of Helicobacter Pylori, as well as a method and the models for oral administration of therapeutically effective amounts of the asiaticoside composition for prevention of colon cancer, gastric diseases and gastric carcinoma.

Abstract: The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from Trigonella foenum-graecum.